When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
In response to the current worldwide pandemic, CytoDyn (CYDY) is frenetically tracking down an FDA approval for its monoclonal antibody, leronlimab in treatment of COVID-19. I was initially quite skeptical of this quest, but I have slowly warmed to the prospect.
As matters now stand, I am waiting and watching with guarded optimism as it goes through the early stages of revealing data from its COVID-19 clinical trials. This article discusses the current status of CytoDyn's COVID-19 quest and explains my bullish outlook for CytoDyn, albeit an outlook that recognizes daunting challenges.